High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of this disease. Targeted treatment has improved outcome, but there is still a need for new therapeutic strategies as some patients respond poorly to treatment. Our aim was to identify compounds that sub...

Description complète

Détails bibliographiques

Auteurs principaux:	Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
Format:	Artigo
Langue:	Inglês
Publié:	Public Library of Science (PLoS) 2023-01-01
Collection:	PLoS ONE
Accès en ligne:	https://doi.org/10.1371/journal.pone.0280507
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!